A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy – Lymphoma Symptom Index

References

• American Cancer Society. Cancer Facts and Figures 2011. Atlanta: American Cancer Society, Inc., 2011.
   Google Scholar
• Siegel R., Ward E, Brawley O, et al. Cancer statistics 2011. CA Cancer J Clin 2011;61:212–236.
   PubMed Web of Science ®Google Scholar
• Hubbard SM, Longo DL. Treatment-related morbidity in patients with lymphoma. Curr Opin Oncol 1991;3:852–862.
   PubMedGoogle Scholar
• Razavi D, Delvaux N, Bredart A, et al. Professional rehabilitation of lymphoma patients: a study of psychosocial factors associated with return to work. Support Care Cancer 1993;1:276–278.
   PubMed Web of Science ®Google Scholar
• Bilodeau BA, Fessele KL. Non-Hodgkin's lymphoma. Semin Oncol Nurs 1998;14:273–283.
   PubMedGoogle Scholar
• Fernsler J, Fanuele JS. Lymphomas: long-term sequelae and survivorship issues. Semin Oncol Nurs 1998;14:321–328.
   PubMedGoogle Scholar
• Lesko L. Hematopoietic dyscrasias. In: Holland HC, editor. Psycho-oncology. New York: Oxford University Press; 1998. pp 406–416.
   Google Scholar
• Van Agthoven M, Vellenga E, Fibbe WE, et al. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory of relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomized trial. Eur J Cancer 2001;37:1781–1789.
   PubMed Web of Science ®Google Scholar
• Voliotis D, Diehl V. Challenges in treating hematologic malignancies. Semin Oncol 2002;29:30–39.
   PubMed Web of Science ®Google Scholar
• Webster K, Cella D. Quality of life in patients with low-grade non-Hodgkin's lymphoma. Oncology 1998;12:697–714.
   PubMed Web of Science ®Google Scholar
• Foster T, Miller JD, Boye ME, et al. Economic burden of follicular non-Hodgkin's lymphoma. Pharmacoeconomics 2009;27:657–679.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Donnatti C, Hoskin P, et al. The impact of follicular lymphoma on health-related quality of life. Ann Oncol 2008;19: 570–576.
   PubMed Web of Science ®Google Scholar
• Smith SK, Zimmerman S, Williams CS, et al. Health status and quality of life among non-Hodgkins lymphoma survivors. Cancer 2009; 115:3312–3323.
   PubMed Web of Science ®Google Scholar
• Smith SK, Crespi CM, Petersen L, et al. The impact of cancer and quality of life for post-treatment non-Hodgkins lymphoma survivors. Psychooncology 2010;19:1259–1267.
   PubMed Web of Science ®Google Scholar
• Crespi CM, Smith SK, Petersen L, et al. Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors. J Cancer Surviv 2010;4:45–58.
   PubMed Web of Science ®Google Scholar
• Orelemans S, Mols F, Nijziel MR, et al. The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkins's and non-Hodgkin's lymphoma survivors: a systemic review. Ann Hematol 2011;90:993–1004.
   PubMed Web of Science ®Google Scholar
• Leak A, Mayer DK, Smith S. Quality of life domains among non-Hodgkin lymphoma survivors: an integrated literature review. Leuk Lymphoma 2011;52:972–985.
   PubMed Web of Science ®Google Scholar
• Yost KJ, Thompson CA, Eton DT, et al. The Functional Assessment of Cancer Therapy-General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2013;54:290–297.
   PubMed Web of Science ®Google Scholar
• Guidance for industry: Patient-reported outcome measures: use in medical product development to support labeling claims. Rockville, MD: US Department of Health and Human Services FDA Center for Drug Evaluation and Research; 2009.
   Google Scholar
• Quality of life ad claims should be specific, FDA-sponsored physician focus groups say: ad division direction cautions against QOL “claim expansiveness.”. FDC Rep 1994;56:8–9.
   Google Scholar
• Hlubocky FJ, Webster K, Cashy J, et al. The development and validation of a measure of health-related quality of life for non-hodgkin's lymphoma: the Functional Assessment of Cancer Therapy – Lymphoma (FACT-Lym). Lymphoma Submitted 2012.
   Google Scholar
• Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999;2:113–126.
   PubMedGoogle Scholar
• Williams G, Pazdur R, Temple R. Assessing tumor-related signs and symptoms to support cancer drug approval. J Biopharm Stat 2004;14:5–21.
   PubMedGoogle Scholar
• Cleeland CS. Symptom burden; multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr 2007;37:16–21.
   PubMedGoogle Scholar
• Cella D, Rosenbloom SK, Beaumont JL, et al. Development and validation of eleven symptom indexes to evaluate response to chemotherapy for advanced cancer. J Natl Compr Cancer Netw 2011;9:13–23.
   PubMed Web of Science ®Google Scholar
• Webster K, Odom L, Peterman A, et al. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res 1999;8:604.
   Google Scholar
• Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79.
   PubMedGoogle Scholar
• Webster K, Cashy J, Cella D, et al. Measuring quality of life (QOL) in patients with non-Hodgkin's Lymphoma (NHL): the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym). Qual Life Res 2005;14:1650.
   Google Scholar
• Ryan G, Bernard HR. Data management and analysis methods. In: Denzin NK, Lincoln YS, editors. Handbook of qualitative research. 2nd ed. Thousand Oaks, CA: Sage Publications; 2000.
   Google Scholar